Enanta Pharmaceuticals In... (ENTA)
5.10
0.17 (3.45%)
At close: Apr 17, 2025, 3:59 PM
3.45% (1D)
| Bid | 4.09 |
| Market Cap | 108.8M |
| Revenue (ttm) | 66.59M |
| Net Income (ttm) | -104.93M |
| EPS (ttm) | -4.95 |
| PE Ratio (ttm) | -1.03 |
| Forward PE | -1.19 |
| Analyst | Buy |
| Ask | 5.46 |
| Volume | 175,018 |
| Avg. Volume (20D) | 362,258 |
| Open | 4.88 |
| Previous Close | 4.93 |
| Day's Range | 4.88 - 5.15 |
| 52-Week Range | 4.09 - 17.23 |
| Beta | 0.70 |
About ENTA
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A pro...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 21, 2013
Employees 131
Stock Exchange NASDAQ
Ticker Symbol ENTA
Website https://www.enanta.com
Analyst Forecast
According to 4 analyst ratings, the average rating for ENTA stock is "Buy." The 12-month stock price forecast is $19, which is an increase of 272.55% from the latest price.
Stock ForecastsNext Earnings Release
Enanta Pharmaceuticals Inc. is scheduled to release its earnings on May 5, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+14.08%
Enanta Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
4 months ago
+11.75%
Enanta Pharmaceuticals shares are trading higher after the company announced topeline results from its first-in-pediatrics Phase 2 study evaluating Zelicapavir for children aged 28 days to 36 months with respiratory syncytial vrius.
